



Office of Continuing Education

Please fill out the form below **IN INK** to verify participation in this CE activity and fax to 713-500-0606. If requesting Nursing credit please also complete the attached Post Test Questions

TOPIC: Lung Cancer Module III & Gastrointestinal Cancers Module IV

DATE: September 23, 2008

SPEAKER: Robert Jotte, M.D., PhD & Thomas Cartwright, M.D.

LOCATION: Enduring Material

OBJECTIVES:

- Revise treatment plans for patients with non-small cell lung cancer based upon recent research findings presented in this activity
- Employ the practice-changing research findings in treatment plans that will provide optimal care of patients with gastrointestinal cancer

DISCLOSURE:

Dr. Jotte is a consultant for Genentech, he is on the Speaker's Bureau for sanofi-aventis and Eli Lilly, and he will discuss unlabeled uses of pemtrexed and cetuximab. Dr. Cartwright receives grant/research support from Roche and BMS, is a consultant for Roche and ImClone, is on the Speaker's Bureau for Roche, Amgen, and ImClone, and will discuss off-labeled uses of cetuximab and panitumumab.

Accreditation: This program has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Texas Medical Branch at Galveston and Oncology Today. The University of Texas Medical Branch at Galveston is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME The University of Texas Medical Branch at Galveston designates this educational activity for a maximum of (1.5) *AMA PRA Category 1 Credit(s)*TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE This program has been approved by the American Association of Critical Care Nurses (AACN) for 1 Contact Hour, Category A, File Number 2008 - (1213b).

ACPE The University of Houston College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing education. Pharmacists documenting completion of the program "Lung Cancer Updates and Updates on Gastrointestinal Cancer" (# 066-999-08-031-L01-P) by signing in, completing evaluations and a post-test exam will receive 1 contact hour (0.1 CEU) pharmacy continuing education credit, and will receive a statement of credit by mail within 3 weeks of UHCOP being notified of the completion date. Initial Release Date: October 10, 2008. Expiration Date: October 10, 2011.

CREDIT CANNOT BE AWARDED UNLESS FORM IS COMPLETELY LEGIBLE

First Name	MI	Last Name	Title
Address: _____			
City: _____		State: _____	Zip: _____
Phone: _____	Fax: _____	Email: _____	

PLEASE COMPLETE EVALUATION FORM BEFORE RETURNING

- Make solid marks that fill the response completely.
- Make no stray marks on this form.

Scale: 1= Strongly Disagree 2= Disagree 3= Agree 4= Strongly Agree

①	②	③	④	The content of this presentation is applicable to my professional development.
①	②	③	④	The course objectives were met.
①	②	③	④	The presentation was clear and understandable.
①	②	③	④	The program was free of commercial bias and presented in an objective manner.
①	②	③	④	The presentation was scientifically based and accurate.
①	②	③	④	As a result of this course, my professional effectiveness will increase.

Disagree ←————→ Agree

Comments for strengths and improvements: _____

6431 Fannin St. JLL 435 | Houston, TX 77030
PHONE (713) 500-5249 | FAX (713) 500-0606 | <http://www.utcmne.net>



ACPE The University of Houston College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing education



Name _____

Please complete the following questions if requesting nursing or pharmacy credit.

Lung Cancer Module III

1. In patients with advanced EGFR expressing NSCLC, the FLEX study demonstrated which of the following to be the superior standard in first line treatment?
 - a. Platinum based chemotherapy alone
 - b. Platinum based chemotherapy in combination with cetuximab

Gastrointestinal Cancers Module IV

2. According to the CONKO – 001 trial, gemcitabine should be the standard of care for adjuvant treatment for patients with pancreatic cancer.
 - a. True
 - b. False

Please fax completed forms to 713-500-0606